These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33646162)

  • 101. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2021 Mar; 17(3):327-406. PubMed ID: 33756057
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Clinical Features and Outcomes of Patients with Dementia Compared to an Aging Cohort Hospitalized During the Initial New York City COVID-19 Wave.
    Harb AA; Chen R; Chase HS; Natarajan K; Noble JM
    J Alzheimers Dis; 2021; 81(2):679-690. PubMed ID: 33749656
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial.
    Bai D; Fan J; Li M; Dong C; Gao Y; Fu M; Huang G; Liu H
    J Alzheimers Dis; 2021; 81(1):155-167. PubMed ID: 33749643
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment.
    Lam J; Jun H; Cho SK; Hanson M; Mattke S
    Alzheimers Dement (Amst); 2021; 13(1):e12159. PubMed ID: 33748394
    [TBL] [Abstract][Full Text] [Related]  

  • 105. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
    Xiao S; Chan P; Wang T; Hong Z; Wang S; Kuang W; He J; Pan X; Zhou Y; Ji Y; Wang L; Cheng Y; Peng Y; Ye Q; Wang X; Wu Y; Qu Q; Chen S; Li S; Chen W; Xu J; Peng D; Zhao Z; Li Y; Zhang J; Du Y; Chen W; Fan D; Yan Y; Liu X; Zhang W; Luo B; Wu W; Shen L; Liu C; Mao P; Wang Q; Zhao Q; Guo Q; Zhou Y; Li Y; Jiang L; Ren W; Ouyang Y; Wang Y; Liu S; Jia J; Zhang N; Liu Z; He R; Feng T; Lu W; Tang H; Gao P; Zhang Y; Chen L; Wang L; Yin Y; Xu Q; Xiao J; Cong L; Cheng X; Zhang H; Gao D; Xia M; Lian T; Peng G; Zhang X; Jiao B; Hu H; Chen X; Guan Y; Cui R; Huang Q; Xin X; Chen H; Ding Y; Zhang J; Feng T; Cantillon M; Chen K; Cummings JL; Ding J; Geng M; Zhang Z
    Alzheimers Res Ther; 2021 Mar; 13(1):62. PubMed ID: 33731209
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Chiotis K; Dodich A; Boccardi M; Festari C; Drzezga A; Hansson O; Ossenkoppele R; Frisoni G; Garibotto V; Nordberg A
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2086-2096. PubMed ID: 33723628
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Prevalence of Central Nervous System-Active Polypharmacy Among Older Adults With Dementia in the US.
    Maust DT; Strominger J; Kim HM; Langa KM; Bynum JPW; Chang CH; Kales HC; Zivin K; Solway E; Marcus SC
    JAMA; 2021 Mar; 325(10):952-961. PubMed ID: 33687462
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Affective symptoms and regional cerebral tau burden in early-stage Alzheimer's disease.
    Tommasi NS; Gonzalez C; Briggs D; Properzi MJ; Gatchel JR; Marshall GA;
    Int J Geriatr Psychiatry; 2021 Jul; 36(7):1050-1058. PubMed ID: 33682933
    [TBL] [Abstract][Full Text] [Related]  

  • 109. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Leuzy A; Ashton NJ; Mattsson-Carlgren N; Dodich A; Boccardi M; Corre J; Drzezga A; Nordberg A; Ossenkoppele R; Zetterberg H; Blennow K; Frisoni GB; Garibotto V; Hansson O
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2121-2139. PubMed ID: 33674895
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI A
    Alden EC; Pudumjee SB; Lundt ES; Albertson SM; Machulda MM; Kremers WK; Jack CR; Knopman DS; Petersen RC; Mielke MM; Stricker NH
    Alzheimers Dement; 2021 Apr; 17(4):584-594. PubMed ID: 33650308
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Neuroanatomical and clinical factors predicting future cognitive impairment.
    Imms P; Chaudhari NN; Chowdhury NF; Wang H; Yu X; Amgalan A; Irimia A
    Geroscience; 2024 Aug; ():. PubMed ID: 39153054
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Association of estimated pulse wave velocity with cognitive function in a multiethnic diverse population: The Northern Manhattan Study.
    Aimagambetova B; Ariko T; Gardener H; Levin B; Sun X; Gutierrez J; Elkind MS; Wright CB; Rundek T
    Alzheimers Dement; 2024 Jul; 20(7):4903-4913. PubMed ID: 38895994
    [TBL] [Abstract][Full Text] [Related]  

  • 113. "Hang Ups, Let Downs, Bad Breaks, Setbacks": Impact of Structural Socioeconomic Racism and Resilience on Cognitive Change Over Time for Persons Racialized as Black.
    Adkins-Jackson PB; Kim B; Higgins Tejera C; Ford TN; Gobaud AN; Sherman-Wilkins KJ; Turney IC; Avila-Rieger JF; Sims KD; Okoye SM; Belsky DW; Hill-Jarrett TG; Samuel L; Solomon G; Cleeve JH; Gee G; Thorpe RJ; Crews DC; Hardeman RR; Bailey ZD; Szanton SL; Manly JJ
    Health Equity; 2024; 8(1):254-268. PubMed ID: 38665381
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Integrating Biomarkers From Virtual Reality and Magnetic Resonance Imaging for the Early Detection of Mild Cognitive Impairment Using a Multimodal Learning Approach: Validation Study.
    Park B; Kim Y; Park J; Choi H; Kim SE; Ryu H; Seo K
    J Med Internet Res; 2024 Apr; 26():e54538. PubMed ID: 38631021
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Sex Differences in Conversion Risk from Mild Cognitive Impairment to Alzheimer's Disease: An Explainable Machine Learning Study with Random Survival Forests and SHAP.
    Sarica A; Pelagi A; Aracri F; Arcuri F; Quattrone A; Quattrone A; For The Alzheimer's Disease Neuroimaging Initiative
    Brain Sci; 2024 Feb; 14(3):. PubMed ID: 38539590
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Contribution of Peripheral Microvascular Dysfunction to Mild Cognitive Impairment.
    Gold ME; Rogers SC; Kulshreshtha A; Chen Y; Ko YA; Cheng ML; Gold DA; Vatsa N; Jain V; Desai S; Moazzami K; Thomas T; Okafor M; Goldstein F; Lah J; Quyyumi AA; Hajjar I
    Am J Cardiol; 2024 May; 218():4-6. PubMed ID: 38452841
    [No Abstract]   [Full Text] [Related]  

  • 117. The prevalence of mild cognitive impairment in Gulf War veterans: a follow-up study.
    Chao LL; Sullivan K; Krengel MH; Killiany RJ; Steele L; Klimas NG; Koo BB
    Front Neurosci; 2023; 17():1301066. PubMed ID: 38318196
    [TBL] [Abstract][Full Text] [Related]  

  • 118. A Community-Based Study of Dementia in Mexican American and Non-Hispanic White Individuals.
    Morgenstern LB; Briceño EM; Mehdipanah R; Chang W; Lewandowski-Romps L; Gonzales XF; Levine DA; Langa KM; Garcia N; Khan N; Zahuranec DB; Heeringa SG
    J Alzheimers Dis; 2024; 97(2):649-658. PubMed ID: 38143352
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Health Disparities in Cognitive Impairment and Dementia: Role of Social Strain, Depression, and C-Reactive Protein.
    Malatyali A; Sagna De Main A; Cidav T; Komalasari R; Xie R; Thiamwong L
    Gerontol Geriatr Med; 2023; 9():23337214231215274. PubMed ID: 38035262
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Explainability of random survival forests in predicting conversion risk from mild cognitive impairment to Alzheimer's disease.
    Sarica A; Aracri F; Bianco MG; Arcuri F; Quattrone A; Quattrone A;
    Brain Inform; 2023 Nov; 10(1):31. PubMed ID: 37979033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.